These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. Schwartz RS; Chronos NA; Virmani R J Am Coll Cardiol; 2004 Oct; 44(7):1373-85. PubMed ID: 15464316 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298 [TBL] [Abstract][Full Text] [Related]
5. Restenosis is not associated with stent length in a pig model of coronary stent implantation. Koutouzis M; Papalois A; Kyrzopoulos S; Dafnomili P; Kyriakides ZS Cardiol J; 2008; 15(5):458-62. PubMed ID: 18810722 [TBL] [Abstract][Full Text] [Related]
6. Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model. Huang Y; Salu K; Wang L; Liu X; Li S; Lorenz G; Wnendt S; Verbeken E; Bosmans J; Van de Werf F; De Scheerder I J Invasive Cardiol; 2005 Mar; 17(3):142-8. PubMed ID: 15867441 [TBL] [Abstract][Full Text] [Related]
7. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model. Ma G; Ding S; Feng Y; Shen C; Chen L; Chen Z J Cardiovasc Pharmacol; 2007 Aug; 50(2):201-5. PubMed ID: 17703137 [TBL] [Abstract][Full Text] [Related]
8. Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems. Perkins LE Vet Pathol; 2010 Jan; 47(1):58-76. PubMed ID: 20080486 [TBL] [Abstract][Full Text] [Related]
10. Biocompatibility of tetramethylpyrazine-eluting stents in normal porcine coronary arteries. Ma GS; Chen LJ; Chen Z; Ding S; Shen CX; Feng Y Biomed Pharmacother; 2008 Feb; 62(2):125-9. PubMed ID: 17764890 [TBL] [Abstract][Full Text] [Related]
11. Neointimal proliferation in canine coronary arteries. A model of restenosis permitting local and continuous drug delivery. Scheinowitz M; Shou M; Banai S; Gertz SD; Lazarous DF; Unger EF Lab Invest; 1994 Dec; 71(6):813-9. PubMed ID: 7632203 [TBL] [Abstract][Full Text] [Related]
12. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Johnson TW; Wu YX; Herdeg C; Baumbach A; Newby AC; Karsch KR; Oberhoff M Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):754-9. PubMed ID: 15681295 [TBL] [Abstract][Full Text] [Related]
13. Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model. Kipshidze NN; Porter TR; Dangas G; Yazdi H; Tio F; Xie F; Hellinga D; Wolfram R; Seabron R; Waksman R; Abizaid A; Roubin G; Iyer S; Colombo A; Leon MB; Moses JW; Iversen P Catheter Cardiovasc Interv; 2005 Mar; 64(3):389-94. PubMed ID: 15736246 [TBL] [Abstract][Full Text] [Related]
14. Stent thrombosis in the era of drug eluting stents. Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of late lumen loss after antiproliferative percutaneous coronary intervention using beta-irradiation in a porcine model of restenosis. Deiner C; Loddenkemper C; Rauch U; Rosenthal P; Pauschinger M; Schwimmbeck PL; Schultheiss HP; Pels K Cardiovasc Revasc Med; 2007; 8(2):94-8. PubMed ID: 17574167 [TBL] [Abstract][Full Text] [Related]
18. Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy. Yamamoto M; Okamatsu K; Inami S; Takano M; Yokoyama S; Ohba T; Ibuki C; Hata N; Seino Y; Mizuno K Am Heart J; 2009 Jul; 158(1):99-104. PubMed ID: 19540398 [TBL] [Abstract][Full Text] [Related]